$25M Upfront for Aligos’ Hepatitis B Drug in China Deal — Aligos Therapeutics, Inc.

Event summary

Aligos Therapeutics received a $25M upfront payment from Xiamen Amoytop Biotech for exclusive rights to pevifoscorvir sodium in Greater China.
Pevifoscorvir sodium was granted Breakthrough Therapy Designation by China’s CDE, accelerating regulatory review.
The deal includes up to $420M in potential milestones and high single-digit royalties on net sales for Aligos.
Aligos retains commercialization rights outside Greater China, including the U.S., Europe, Japan, and South Korea.

The big picture

This deal underscores the strategic importance of China’s biopharma market, where regulatory incentives like Breakthrough Therapy Designation can fast-track drug approvals. Aligos’ ability to secure a high-value partnership while retaining global rights outside Greater China positions it competitively in the chronic hepatitis B space.

What we're watching

Regulatory Momentum: Whether Breakthrough Therapy Designation will expedite pevifoscorvir sodium’s approval in China and other markets.
Revenue Potential: The pace at which milestone payments and royalties could materialize, given the $420M upside.
Pipeline Progress: How Aligos’ collaboration with Amoytop on ALG-170675 will impact its broader hepatitis B pipeline.